Medicenna Therapeutics Corp. (MDNAF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Fahar Merchant Ph.D. | Founder, Chairman, President & CEO | 333.35k | -- | 1957 |
| Ms. Rosemina Merchant B.Sc., M.E.Sc | Founder & Chief Development Officer | 267.39k | -- | 1957 |
| Mr. David Hyman CA, CBV | Chief Financial Officer | -- | -- | 1973 |
| Dr. Samuel R. Denmeade M.D. | Scientific Advisor | -- | -- | -- |
Medicenna Therapeutics Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 16
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Corporate Governance
Upcoming Events
June 25, 2024 at 12:30 PM UTC - July 1, 2024 at 12:30 PM UTC
Medicenna Therapeutics Corp. Earnings Date
Recent Events
May 10, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
April 22, 2024 at 12:00 AM UTC
AW: Withdrawal of amendment to a registration statement filed under the Securities Act